Extended Data Fig. 1: Participant Disposition in the PASSPORT study. | Nature Medicine

Extended Data Fig. 1: Participant Disposition in the PASSPORT study.

From: Safety and efficacy of anti-tau monoclonal antibody gosuranemab in progressive supranuclear palsy: a phase 2, randomized, placebo-controlled trial

Extended Data Fig. 1

Percentages are based on the number of participants who received study drug. *Three participants randomly assigned to placebo received one dose of gosuranemab. †One participant assigned to placebo was not dosed due to abnormal vital signs, and three participants assigned to gosuranemab were not dosed because they failed to meet randomization criteria.

Back to article page